U.S. Department of Defense Recommends Phase I Clinical Study of Neumedicines' Interleukin-12 as a Treatment for Wound Healing and Infections for... , a privately held biotechnology company, announced that their proposal to conduct a phase I clinical study of recombinant human interleukin-12 for the treatment of traumatic wounds has been recommended ... (more)
http://ift.tt/1uXYIFf
http://ift.tt/1uXYIFf
No comments:
Post a Comment